EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center

Anam A Mazharuddin, Andrew T Whyte, Dan S Gombos, Nimisha Patel, Azadeh Razmandi, Amina L Chaudhry, Nagham S Al-Zubidi

Journal of Immunotherapy and Precision Oncology · 01.11.2022 · 5 (4) · 98-104

DOI: 10.36401/jipo-22-14 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 30.11.2022. Verfasst von Anam A Mazharuddin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Texas Medical Branch, Galveston, TX, USA. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and clinical outcomes of ocular irAEs.

Methods

In this retrospective, observational case series, we reviewed the medical records of 1280 patients at a large US tertiary cancer center between 2010 and 2020.

Results

We identified 130 patients who presented with ocular irAEs (10%) with 69 males (53%) and 61 females (47%). The mean time to toxicity was 6.1 months. Adverse events include corneal toxicity (31%), neuro-ophthalmic (14%), uveitis and scleritis (13%), retinopathy (13%), periocular disorders (11%), and others. IrAEs occurred most frequently with nivolumab (26%). Most ocular irAEs were treated with topical therapy. Advanced cases required systemic corticosteroids and even cessation of ICIs.

Conclusion

Our cohort is a large case series highlighting the increased potential of ocular toxicity associated with ICIs. Prompt recognition and management of ocular irAEs can minimize their effect.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmunotherapy side effectsnivolumabocular immune-related adverse eventsocular toxicity

Autor:innen und Institutionen

  • Department of Ophthalmology, University of Texas Medical Branch, Galveston, TX, USA.
  • Department of Head and Neck Surgery, Section of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA.
  • Department of Ophthalmology, Weill Cornell Medicine, New York, NY, USA.

Zitieren

APA

Mazharuddin, A. A., Whyte, A. T., Gombos, D. S., Patel, N., Razmandi, A., Chaudhry, A. L., & Al-Zubidi, N. S. (2022). Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center. Journal of Immunotherapy and Precision Oncology, 5(4), 98-104. https://doi.org/10.36401/jipo-22-14

Vancouver

Mazharuddin AA, Whyte AT, Gombos DS, Patel N, Razmandi A, Chaudhry AL, et al. Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center. Journal of Immunotherapy and Precision Oncology. 2022;5(4):98-104. doi:10.36401/jipo-22-14

BibTeX
@article{Mazharuddin2022,
  author = {Mazharuddin, Anam A and Whyte, Andrew T and Gombos, Dan S and Patel, Nimisha and Razmandi, Azadeh and Chaudhry, Amina L and Al-Zubidi, Nagham S},
  title = {Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2022},
  volume = {5},
  number = {4},
  pages = {98--104},
  doi = {10.36401/jipo-22-14}
}
Kostenlos starten →